Millennium Management LLC Has $1.08 Million Position in Deciphera Pharmaceuticals Inc (DCPH)

Millennium Management LLC reduced its holdings in Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) by 88.6% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 27,361 shares of the company’s stock after selling 213,700 shares during the quarter. Millennium Management LLC’s holdings in Deciphera Pharmaceuticals were worth $1,077,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Orbimed Advisors LLC grew its holdings in Deciphera Pharmaceuticals by 30.8% in the second quarter. Orbimed Advisors LLC now owns 2,005,700 shares of the company’s stock valued at $78,924,000 after purchasing an additional 472,800 shares during the period. Redmile Group LLC grew its holdings in Deciphera Pharmaceuticals by 79.9% in the second quarter. Redmile Group LLC now owns 1,477,080 shares of the company’s stock valued at $58,123,000 after purchasing an additional 655,800 shares during the period. FMR LLC grew its holdings in Deciphera Pharmaceuticals by 33.5% in the second quarter. FMR LLC now owns 1,182,091 shares of the company’s stock valued at $46,515,000 after purchasing an additional 296,571 shares during the period. Emerald Advisers Inc. PA grew its holdings in Deciphera Pharmaceuticals by 23.0% in the second quarter. Emerald Advisers Inc. PA now owns 592,224 shares of the company’s stock valued at $23,304,000 after purchasing an additional 110,785 shares during the period. Finally, BlackRock Inc. grew its holdings in Deciphera Pharmaceuticals by 18.2% in the second quarter. BlackRock Inc. now owns 591,064 shares of the company’s stock valued at $23,258,000 after purchasing an additional 91,185 shares during the period. 53.56% of the stock is currently owned by institutional investors.

Several analysts have commented on DCPH shares. Cantor Fitzgerald started coverage on Deciphera Pharmaceuticals in a report on Thursday, September 6th. They issued a “buy” rating and a $53.00 price objective on the stock. Canaccord Genuity set a $55.00 price objective on Deciphera Pharmaceuticals and gave the company a “buy” rating in a report on Monday, August 13th. Zacks Investment Research raised Deciphera Pharmaceuticals from a “hold” rating to a “buy” rating and set a $41.00 price objective on the stock in a report on Tuesday, July 24th. Guggenheim started coverage on Deciphera Pharmaceuticals in a report on Monday, September 17th. They issued a “buy” rating on the stock. Finally, ValuEngine raised Deciphera Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, October 2nd. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and nine have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $45.44.

NASDAQ DCPH opened at $20.41 on Friday. Deciphera Pharmaceuticals Inc has a 1-year low of $15.15 and a 1-year high of $45.61. The company has a debt-to-equity ratio of 0.05, a quick ratio of 18.44 and a current ratio of 18.44.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last released its earnings results on Tuesday, August 7th. The company reported ($0.65) earnings per share for the quarter, beating the consensus estimate of ($0.68) by $0.03. As a group, research analysts anticipate that Deciphera Pharmaceuticals Inc will post -2.61 earnings per share for the current year.

Deciphera Pharmaceuticals Company Profile

Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, and other solid tumors.

Featured Story: Earnings Per Share

Want to see what other hedge funds are holding DCPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Deciphera Pharmaceuticals Inc (NASDAQ:DCPH).

Institutional Ownership by Quarter for Deciphera Pharmaceuticals (NASDAQ:DCPH)

Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply